CORI Corium International, Inc. (delisted)

Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Robert Breuil, Corium’s Chief Financial Officer, will present at the Dawson James Securities Growth Stock Conference in Jupiter, Florida, on Thursday, October 20, 2016 at 8:30 a.m. Eastern time.

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems.  Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease.  Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma, Endo Pharmaceuticals and Procter & Gamble.  The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.  The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with other partners.  For further information, please visit www.coriumgroup.com. Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.

Investor and Media Contact:
SMP Communications
Susan Pietropaolo
susan@smpcommunications.com
(201) 923-2049